WO2017183559A1

WO2017183559A1 - Transmucosal absorption promoter for drug

Info

Publication number: WO2017183559A1
Application number: PCT/JP2017/015181
Authority: WO
Inventors: 真莉子武田; 敬泰亀井
Original assignee: 学校法人神戸学院
Priority date: 2016-04-19
Filing date: 2017-04-13
Publication date: 2017-10-26
Also published as: JPWO2017183559A1; TW201815410A

Abstract

The present invention addresses the problem of providing a transmucosal absorption promoter for a drug. This problem is solved by using at least one member selected from the group consisting of: (component a) a basic amino acid; (component b) a peptide consisting of 2-5 basic amino acids; and (component c) tryptophan.

Description

Drug transmucosal absorption enhancer

The present invention relates to a transmucosal absorption promoter for drugs, a pharmaceutical composition containing the same, and the like.

With the rapid development of the biomarket in the 21st century, the introduction of innovative Drug 革新 Delivery (DDS) technology for the efficient absorption of macromolecules such as peptides, proteins and nucleic acid drugs into the body There is more demand. In particular, although the development of oral preparations that are most convenient for patients is desired, it is the most difficult to make oral preparations of substances with extremely low transmucosal absorbability and stability, such as biopharmaceuticals. The current situation is limited to injection administration. For this reason, there is a strong demand for the development of means for promoting transmucosal absorbability of biopharmaceuticals and the like.

Conventionally, it has been reported that transmucosal absorbability of biopharmaceuticals and the like can be promoted by causing destabilization of the membrane structure and release of intercellular tight junctions using, for example, certain surfactants (non-patented). References 1-2). However, these techniques may adversely affect the living body due to the principle.

In recent years, it has been reported that the introduction of bio-drugs into cells can be promoted by using various cell membrane-penetrating peptides (cell-penetrating peptides (CPPs)) such as TAT peptides and penetratin (Non-patent Document 3). However, many of these peptides promote the transmucosal absorption of a drug by being used by crosslinking with the drug. For example, a product obtained by crosslinking arginine hexapeptide, which is a cell membrane permeable peptide, to the C-terminal side of leuprolide, which is a prostate cancer therapeutic agent, is known (Non-patent Document 4). For this reason, this technique has low versatility, and there is a possibility that the activity of the drug is reduced by crosslinking.

The present inventors have reported that cell membrane permeation peptides such as arginine oligopeptide can promote transmucosal absorbability of a drug by simply mixing it with the drug (Non-patent Document 5). With this technique, since crosslinking is not required, there is a low possibility that the above problems will occur. Regarding arginine oligopeptides, peptides composed of 6 or more arginines such as decapeptides, octapeptides, hexapeptides have been reported so far. Among these, octapeptide and decapeptide show high transmucosal absorption promoting action, but it is said that hexapeptide having a smaller number of arginine residues has lower transmucosal absorbability (Non-patent Document 5).

An object of the present invention is to provide an agent for promoting transmucosal absorption of a drug. It is another object of the present invention to provide a transmucosal absorption promoter that does not require crosslinking with a drug and has less adverse effects on the living body.

As a result of intensive studies in view of the above problems, the present inventors have found that basic amino acids such as arginine and basic amino acid oligopeptides having fewer residues than previously reported (ie, having 5 or less residues), It has been found that it exerts a high transmucosal absorption promoting action on drugs. Conventionally, it was said that when the number of basic amino acid residues is smaller, the transmucosal absorption promoting action is also lower (Non-Patent Document 5), and this finding of the present invention was surprising. Furthermore, it discovered that tryptophan exhibited the high transmucosal absorption promotion effect with respect to a drug. As a result of further research based on these findings, the present invention was completed.

That is, the present invention includes the following embodiments:
Item 1. Transmucosal absorption of a drug comprising (a component) a basic amino acid, (b component) a peptide composed of 2 to 5 basic amino acids, and (c component) at least one selected from the group consisting of tryptophan Accelerator.
Item 2. Item 2. The transmucosal absorption promoter according to Item 1, wherein the basic amino acid is an L-amino acid. Item 3. Item 3. The transmucosal absorption promoter according to

Item

1 or 2, comprising the component a.
Item 4. Item 4. The transmucosal absorption enhancer according to any one of Items 1 to 3, wherein the basic amino acid is at least one selected from the group consisting of arginine, lysine, and histidine.
Item 5. Item 5. The transmucosal absorption promoter according to any one of Items 1 to 4, wherein the basic amino acid is arginine.
Item 6. Item 6. The transmucosal absorption promoter according to any one of Items 1 to 5, wherein the component b is a peptide composed of 2 to 4 basic amino acids.
Item 7. Item 7. The transmucosal absorption promoter according to any one of Items 1 to 6, comprising the component c.
Item 8. Item 8. The transmucosal absorption enhancer according to any one of Items 1 to 7, wherein the mucosa is intestinal mucosa.
Item 9. Item 9. The transmucosal absorption promoter according to any one of Items 1 to 8, wherein the drug has an isoelectric point of 7 or less.
Item 10. Item 10. The transmucosal absorption enhancer according to any one of Items 1 to 9, wherein the drug is a peptide or protein.
Item 11. Item 11. A pharmaceutical composition comprising the transmucosal absorption promoter according to any one of Items 1 to 10 and a drug.
Item 12. Item 12. The pharmaceutical composition according to Item 11, which is a solid agent.
Item 13. Item 13. The pharmaceutical composition according to Item 11 or 12, which is an oral administration preparation.

According to the present invention, it is possible to provide a transmucosal absorption promoter that does not require crosslinking with a drug and has less adverse effects on the living body.

Many drugs, such as bio-drugs, are provided as injections because of their low transmucosal absorbability, but injections require the act of sticking a needle, which can be a burden on patients. Is big. In addition, disposal after the use of a syringe places an economic burden and an environmental burden, and in developing countries, there is a possibility of infectious diseases caused by reusing the syringe. According to the present invention, by improving the transmucosal absorbability of a drug, the drug can be provided in a formulation form (for example, an oral preparation) in which the above problems are less likely to occur.

The result of Test Example 1 is shown. The vertical axis represents the human insulin concentration in plasma, the horizontal axis represents the elapsed time after administration, and each data represents mean ± SEM (n = 3-5). “Insulin” indicates Comparative Example 1, “LR” indicates Example 1, “L-R2” indicates Example 2, “L-R4” indicates Example 3, and “L-R8” indicates Comparative Example 2 (Table 1). reference). The result of Test Example 2 is shown. The vertical axis indicates the human insulin concentration in plasma, the horizontal axis indicates the elapsed time after administration, and each data indicates an average value ± SEM (n = 4). “0 μm” represents Comparative Example 1, “8 μm” represents Example 1, “16 μm” represents Example 4, and “40 μm” represents Example 5 (see Table 2). The result of Test Example 3 is shown. The vertical axis represents the human insulin concentration in plasma, the horizontal axis represents the elapsed time after administration, and each data represents mean ± SEM (n = 3-4). "Insulin" indicates Comparative Example 1, "L-R" indicates Example 1, "L-K" indicates Example 6, and "L-H" indicates Example 7 (see Table 3). The result of Test Example 4 is shown. The horizontal axis represents the LDH (lactate dehydrogenase) concentration in the intestinal fluid, and each data represents the mean ± SEM (n = 4). “PBS” represents Solution 1, “Insulin” represents Solution 2, “L-R” represents Solution 3, and “Sodium taurodeoxycholate” represents Solution 4. The result of Test Example 5 is shown. The horizontal axis shows a value obtained by dividing TEER (T ₁₂₀ ) after the test by TEER (T ₀ ) at the start of the test and multiplying by 100, and each data shows an average value ± SEM (n = 4). The case where test solution 1, test solution 2, test solution 3, test solution 4, test solution 5, and test solution 6 are used in order from the top is shown. The result of Test Example 6 is shown. The vertical axis shows the human insulin concentration in plasma, the horizontal axis shows the elapsed time after administration, and each data shows mean value ± SEM (n = 2-4). “Insulin” indicates Comparative Example 1, “L-R1” indicates Example 5, and “L-R1 + L-W1” indicates Example 8 (see Table 4). The result of Test Example 7 is shown. The vertical axis represents the human insulin concentration in plasma, the horizontal axis represents the elapsed time after administration, and each data represents mean ± SEM (n = 2-6). “Insulin” indicates Comparative Example 1, “16 μm” indicates Example 9, and “32 μm” indicates Example 10 (see Table 5). The result of Test Example 8 is shown. The vertical axis represents the human insulin concentration in plasma, the horizontal axis represents the elapsed time after administration, and each data represents mean ± SEM (n = 2-6). “Insulin” represents Comparative Example 1, “16 μm” represents Example 11, and “32 μm” represents Example 12 (see Table 6). The result of Test Example 9 is shown. The vertical axis represents the LDH (lactate dehydrogenase) concentration in the intestinal fluid, and each data represents the mean ± SEM (n = 3). “PBS” is solution A, “Insulin” is solution B, “+ L-R1 (40 mM)” is solution C, “+ L-W1 (16 mM)” is solution D, and “+ L-W1 (32 mM)” is Solution E, “+ L-R1 (40 mM) + L-W1 (50 mM)” represents solution F, and “Sodium taurodeoxycholate” represents solution G. The result of Test Example 10 is shown. The vertical axis shows the relative value of the blood glucose level when the pre-administration value is 100%, the horizontal axis shows the elapsed time after the administration, and each data shows the mean value ± SEM (n = 4-6) Show. “L-R1” represents L-arginine.

In this specification, the expressions “containing” and “including” include the concepts of “containing”, “including”, “consisting essentially of”, and “consisting only of”.

The present invention relates to a drug comprising (a component) a basic amino acid, (b component) a peptide composed of 2 to 5 basic amino acids, and (c component) at least one selected from the group consisting of tryptophan A transmucosal absorption enhancer (also referred to herein as “the transmucosal absorption enhancer of the present invention”), and a pharmaceutical composition (the present invention) containing the transmucosal absorption enhancer of the present invention and a drug. In the specification, it may be referred to as “the pharmaceutical composition of the present invention”). These will be described below.

The basic amino acid is not particularly limited as long as the amino acid has a basic functional group in the side chain and an isoelectric point in the alkaline region (preferably an α-amino acid).

Examples of the basic functional group include a guanidino group, an amino group, an imidazolyl group and the like, preferably a guanidino group and an amino group, and more preferably a guanidino group.

The isoelectric point of the basic amino acid is, for example, more than 7, preferably 7.5 or more, more preferably 9 or more, and further preferably 10 or more. Although the upper limit of an isoelectric point is not specifically limited, For example, it is 14.

Specific examples of basic amino acids include natural amino acids such as arginine, lysine, histidine, ornithine and citrulline. Among these, from the viewpoint of promoting transmucosal absorption, arginine, lysine and the like are preferable, and arginine is more preferable.

The configuration of the basic amino acid is not particularly limited, and may be either L-form or D-form. From the viewpoint that the transmucosal absorption promoting effect is higher and / or the transmucosal absorption promoting effect is further improved in a dose-dependent manner, the basic amino acid is preferably an L-amino acid.

A peptide composed of basic amino acids is a peptide formed by peptide bonding of a plurality of basic amino acids (preferably an amino group and a carboxyl group on the main chain of the basic amino acid), and is not particularly limited as long as this is the case. .

The number of basic amino acids constituting the peptide is 2-5, preferably 2-4.

The peptide may be composed of only one basic amino acid or may be composed of two or more basic amino acids.

The configuration of tryptophan is not particularly limited, and may be either L-form or D-form. From the viewpoint that the transmucosal absorption promoting effect is higher and / or the transmucosal absorption promoting effect is further improved in a dose-dependent manner, tryptophan is preferably L-form.

The basic amino acid, the peptide composed of the basic amino acid, and tryptophan may be chemically modified as long as they have a transmucosal absorption promoting effect. In addition, the presence or absence of the transmucosal absorption promoting effect can be determined according to or according to a known method. For example, it can be determined according to or according to the method described in Test Example 1 described later.

In basic amino acids, peptides composed of basic amino acids, and tryptophan, the carboxyl group at the end of the main chain is either carboxylate (—COO ⁻ ), amide (—CONH ₂ ) or ester (—COOR) Also good.

Here, as R in the ester, for example, a C _1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, n-butyl; for example, a C _3-8 cycloalkyl group such as cyclopentyl, cyclohexyl; C _6-12 aryl groups such as α-naphthyl; phenyl-C _1-2 alkyl groups such as benzyl and phenethyl; C _7- such as α-naphthyl-C _1-2 alkyl groups such as α-naphthylmethyl; ₁₄ aralkyl group; pivaloyloxymethyl group and the like are used.

Further, basic amino acids, peptides composed basic amino acids, and tryptophan, the main chain terminal amino group protecting group (e.g., formyl groups, C such as C _1-6 alkanoyl such as acetyl group _1-6 An acyl group or the like, or a substituent on the side chain (for example, an amino group, an imidazolyl group or a guanidino group) is an appropriate protecting group (for example, a C _1-6 alkanoyl group such as a formyl group or an acetyl group) And the like protected with a C _1-6 acyl group such as and the like.

The basic amino acid, the peptide composed of the basic amino acid, and tryptophan may be in the form of a pharmaceutically acceptable salt with an acid or a base. The salt is not particularly limited as long as it is a pharmaceutically acceptable salt, and either an acidic salt or a basic salt can be employed. Examples of acid salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, nitrate and phosphate; acetate, propionate, tartrate, fumarate, maleate, apple Organic acid salts such as acid salts, citrate salts, methanesulfonate salts, and paratoluenesulfonate salts; and amino acid salts such as aspartate salts and glutamate salts. Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts.

The basic amino acid, the peptide composed of the basic amino acid, and tryptophan may be in the form of a solvate. The solvent is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include water, ethanol, glycerol, acetic acid and the like.

Basic amino acids (component a) can be used singly or in combination of any two or more.

A peptide composed of basic amino acids (component b) can be used alone or in combination of any two or more.

Tryptophan (component c) can be used singly or in combination of any two or more.

The transmucosal absorption promoter of the present invention is not particularly limited as long as it contains at least one selected from the group consisting of a component, b component, and c component as an active ingredient. From the viewpoint that the transmucosal absorption promotion effect is higher, and / or from the viewpoint that the living body is inoculated daily and the safety is higher, the transmucosal absorption promoter of the present invention has an a component and a c component as active ingredients. It is preferable to contain at least one selected from the group consisting of, more preferably only at least one selected from the group consisting of a component and c component as active ingredients, and only c component as active ingredients It is more preferable to contain.

As the a component, the b component, and the c component, commercially available products can be used as they are, or they can be produced according to or according to a known synthesis method.

Although a limited interpretation is not desired, the mechanism of the present invention in the case of employing the a component and the b component is considered as follows. Known cell membrane permeable peptides that contain many basic amino acids, such as arginine octapeptide, improve the transmucosal absorbability of the drug by forming a complex with the drug due to its positive charge and permeating the cell membrane (Non-Patent Documents 6 and 7). Therefore, the a component and the b component, which are effective components of the present invention, also have a positive charge, and are considered to exhibit the effect based on the same mechanism.

Therefore, the drug targeted by the transmucosal absorption enhancer of the present invention has biological activity, particularly when the a component and the b component are adopted, and is combined with the a component and / or the b component by electrical interaction. The drug is not particularly limited as long as it is a drug capable of forming a body. For example, the isoelectric point (pI) is from a neutral region to an acidic region, preferably pI: 7 or less (or less than 7), more preferably pI: 7 to 0.01. More preferably, the drug has a pI of 6 to 0.1, and even more preferably a pI of 6 to 1.

The molecular weight of the drug is not particularly limited. For example, a drug having a molecular weight of 100 to 1000000, preferably 300 to 200000, more preferably 800 to 100000, still more preferably 1500 to 50000, and still more preferably 2000 to 10,000 can be mentioned.

Specific examples of drugs include peptides, proteins, sugars, polysaccharides, nucleic acids, low molecular compounds, and the like. More specifically, for example, insulin, gastrin, Exendin-4, GLP1, leuprolide, calcitocin, interferon β, PEGylated protein, dextran, nanoparticles and the like can be mentioned.

The mucosa that is the target of the transmucosal absorption enhancer of the present invention is not particularly limited. Examples of the mucosa include intestinal mucosa, gastric mucosa, nasal mucosa, oral mucosa, lung mucous membrane, and the like, preferably intestinal mucosa.

The pharmaceutical composition of the present invention is not particularly limited as long as it contains the above-described transmucosal absorption promoter of the present invention and a drug, and may contain other components as necessary. The other components are not particularly limited as long as they are pharmaceutically acceptable components. For example, bases, carriers, solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders , Disintegrating agents, lubricants, thickeners, moisturizers, coloring agents, fragrances, chelating agents and the like.

The dosage form of the pharmaceutical composition of the present invention is not particularly limited as long as it is a dosage form that can be absorbed from mucous membranes. For example, tablets, capsules, granules, powders, fine granules, syrups, intestinal solvents Oral preparations such as sustained release capsules, chewing tablets, drops, pills, liquids for internal use, confectionery tablets, sustained release agents, sustained release granules, etc .; nasal drops, inhalants, rectal suppositories, inserts, External preparations such as enemas and jelly agents can be mentioned. In addition, the pharmaceutical composition of the present invention may be any of a solid agent, a semisolid agent and a liquid agent, preferably a solid agent and a semisolid agent, more preferably a solid agent.

The content of the drug in the pharmaceutical composition of the present invention depends on the type of drug, the subject to be administered, the administration route, the dosage form, the patient's condition, the judgment of the doctor, etc., and is not limited, for example, For example, it can be 0.0001 to 95% by weight, preferably 0.001 to 50% by weight.

The total content of component a and component b in the pharmaceutical composition of the present invention depends on the type of drug, administration subject, administration route, dosage form, patient condition, doctor's judgment, etc. For example, it may be 0.0001 to 95% by weight, preferably 0.001 to 50% by weight.

A component and b component can exhibit the effect relatively at least. From such a point of view, the pharmaceutical composition of the present invention has a total dose of component a and component b per 1 kg body weight of the subject to be administered, for example, 1 μg to 200 mg, preferably 10 μg to 150 mg, more preferably 100 μg. It is preferably used in an amount of ˜100 mg, more preferably 500 μg˜50 mg.

Hereinafter, the present invention will be described in detail based on examples, but the present invention is not limited to these examples.

Test Example 1 : Evaluation of transmucosal absorption promoting action of arginine or arginine peptide < Test Example 1-1 : Preparation of administration solution>
Various amounts of recombinant human insulin (27.5 IU / mg) (manufactured by Wako Pure Chemical Industries, Ltd.) were dissolved in 50 μL of a 0.1N aqueous hydrochloric acid solution in a polypropylene tube, and this was then added to 1.4% containing methylcellulose at a concentration of 0.001%. The solution was diluted with mL of PBS solution (pH 6.0), and further standardized with 50 μL of 0.1N sodium hydroxide aqueous solution to obtain an insulin solution. On the other hand, various amounts of basic amino acid (L-arginine) (manufactured by Wako Pure Chemical Industries, Ltd.) or various amounts of basic amino acid oligopeptide (2 mer, 4 mer, or 8 mer) are used as a test substance in polypropylene tubes. Then, this was dissolved in a PBS solution (pH 6.0) containing methylcellulose at a concentration of 0.001% to obtain a test substance solution. The insulin solution obtained as described above was used as it was, or a solution obtained by mixing equal amounts of the insulin solution and the test substance solution obtained as described above was used as an administration solution in the following administration tests.

< Test Example 1-2 : Administration test>
A male SD (Sprague Dawley) rat (body weight 180-220 g) (manufactured by SLC) was used for the administration test. A midline incision was made in the abdomen of the anesthetized rat fixed on the plate to expose the ileum. A cannula was inserted proximal to the ileocecum and ligated tightly to prevent fluid loss and then returned to its original position in the abdominal cavity. PBS (37 ° C.) was circulated through the cannula (5.0 mL / min, 4 minutes) using an infusion pump. The cannula tube was removed and the part closed. In order to reverse the increase in blood glucose level due to surgery, the rat was left for 30 minutes. Thereafter, 0.5 mL of the administration solution obtained in Test Example 1-1 was directly administered into the ileal loop. Table 1 shows the insulin dose and the type and concentration of the test substance in the administration solution. The concentrations of the test substances in Examples 1 to 3 and Comparative Example 2 are adjusted so that the concentrations when converted to arginine monomers are the same (8 mM).

< Test Example 1-3 : Evaluation of transmucosal absorption promoting action>
In Test Example 1-2, blood was collected before administration and after 5, 10, 15, 30, 60, 120, and 180 minutes after administration. The obtained blood was centrifuged (13,400 g, 1 minute) to obtain plasma. The concentration of human insulin in plasma (ie, insulin that was administered and then absorbed through the intestinal mucosa) was measured using a human insulin ELISA kit (Mercodia). The measurement results are shown in FIG. As shown in FIG. 1, insulin absorption was enhanced by administering arginine or arginine oligopeptide with insulin. Further, the order of the strength of the absorption promoting action is as follows: arginine (Example 1: LR)> arginine dipeptide (Example 2: L-R2)> arginine tetrapeptide (Example 3: L-R4)> arginine octapeptide ( Comparative Example 2: L-R8).

Test Example 2 : Evaluation of dose-dependent transmucosal absorption promoting action of arginine Tests were conducted in the same manner as in Test Example 1 except that the types and concentrations of the test substances in the administration solution were as shown in Table 2. The results are shown in FIG. As shown in FIG. 2, arginine promoted insulin absorption in a dose-dependent manner.

Test Example 3 : Evaluation of transmucosal absorption promoting action of basic amino acid Test was conducted in the same manner as in Test Example 1 except that the type and concentration of the test substance in the administration solution were as shown in Table 3. The results are shown in FIG. As shown in FIG. 3, even basic amino acids other than arginine promoted insulin absorption. Moreover, the order of the strength of the absorption promoting action was arginine (Example 1: LR)> lysine (Example 6: LK)> histidine (Example 7: LH).

Test Example 4 : Evaluation of the effect of intestinal epithelial tissue on integrity 1
After Test Example 1, the ileum was treated with 20 mL of PBS (37 ° C.) and then air was passed through. 0.5 mL of the solution was administered directly into the ileal loop. There are four types of solutions used for administration:
Solution 1: PBS
Solution 2: PBS containing insulin (insulin content: 50 IU / body weight (kg))
Solution 3: PBS containing L-arginine at a concentration of 40 mM
Solution 4: PBS containing sodium taurodeoxycholate at a concentration of 5% (w / v).

After 3 hours from administration, the ileal loop was washed with 5.0 mL of PBS, and the intestinal fluid was collected. The concentration of LDH (lactate dehydrogenase) in the intestinal fluid was measured using an LDH kit. The measurement results are shown in FIG. As shown in FIG. 4, the LDH concentration in the intestinal fluid was much higher when sodium taurodeoxycholate, which is a positive control, was administered, compared to when PBS was administered. This indicates that the integrity of the intestinal epithelium was disrupted by sodium taurodeoxycholate, so that LDH originally present in the blood leaked through the intestinal epithelium. In contrast, the LDH concentration in the intestinal fluid when arginine was administered was almost unchanged from that when PBS was administered. It was shown to be a high component.

Test Example 5 : Evaluation 1 of the effect of the epithelial tissue on the tight junction structure
The influence of the test substance on the tight junction structure was evaluated based on the electrical resistance (TEER) of the cultured cell layer after the test substance such as arginine was allowed to act. Specifically, it was performed as follows.

Human colon cancer-derived cells (Caco-2 cells) are seeded in a 12-well transwell plate (1.0 × 10 ⁵ cells / cm ² ) and cultured in DMEM medium for 21 days (constant TEER (> 500 Ωcm ² ) (single It was shown that tight junctions were formed in the layer. 500 μL of transport buffer 1 (HBSS buffered with 10 mM MES) was added to the apical side of the transwell, and buffered with 1.5 mL of transport buffer 2 (10 mM HEPES (pH 7.4)) on the basal side HBSS) was added and a 30 minute preincubation was performed. After pre-incubation, TEER was measured using a voltage resistance meter (Millicell ERS-2, manufactured by Millipore), and the obtained value was defined as TEER (T ₀ ) at the start of the test. 100 μL of the apical side transport buffer 1 was replaced with 100 μL of a test substance-containing test solution, and incubated for 2 hours. The types and concentrations of the test substances in the chamber on the apical side after replacement with the test solution are as follows:
Test solution 1: insulin 15μM
Test solution 2: insulin 15 μM, L-arginine 480 μM
Test solution 3: insulin 15 μM, L-arginine 960 μM
Test solution 4: insulin 15 μM, D-arginine 480 μM
Test solution 5: insulin 15 μM, D-arginine 960 μM
Test solution 6: insulin 15 μM, D-arginine octapeptide 60 μM.

After the incubation, TEER was measured using a voltage resistance meter (Millicell ERS-2, manufactured by Millipore), and the obtained value and TEER (T ₁₂₀ ) after the test were obtained. FIG. 5 shows a value obtained by dividing TEER (T ₁₂₀ ) after the test by TEER (T ₀ ) at the start of the test and multiplying by 100. As shown in FIG. 5, there was almost no change in TEER even when arginine was allowed to act at a very high concentration. From this, it was shown that arginine is a highly safe component that has very little influence on the tight junction structure of the intestinal epithelial tissue.

Test Example 6 : Evaluation of transmucosal absorption promoting effect by combined use of basic amino acid and tryptophan Test was conducted in the same manner as in Test Example 1 except that the type and concentration of the test substance in the administration solution were as shown in Table 4. The results are shown in FIG. As shown in FIG. 6, insulin absorption was further promoted by using tryptophan in combination with a basic amino acid.

Test Example 7 : Evaluation of transmucosal absorption promoting action of L-tryptophan alone Tested in the same manner as in Test Example 1 except that the type and concentration of the test substance in the administration solution were as shown in Table 5. The results are shown in FIG. As shown in FIG. 7, L-tryptophan further promoted insulin absorption.

Test Example 8 : Evaluation of transmucosal absorption promoting action of D-tryptophan alone Tested in the same manner as in Test Example 1 except that the type and concentration of the test substance in the administration solution were as shown in Table 6. The results are shown in FIG. As shown in FIG. 8, insulin absorption was further promoted by D-tryptophan.

Test Example 9 : Evaluation of the effect of intestinal epithelial tissue on the integrity 2
The test was conducted in the same manner as in Test Example 4 except that the following seven solutions were used as the administration solutions:
Solution A: PBS containing methylcellulose at a concentration of 0.001%
Solution B: PBS containing insulin (insulin content: 50 IU / body weight (kg))
Solution C: PBS containing L-arginine at a concentration of 40 mM
Solution D: PBS containing L-tryptophan at a concentration of 16 mM
Solution E: PBS containing L-tryptophan at a concentration of 32 mM
Solution F: PBS containing L-arginine at a concentration of 40 mM and L-tryptophan at a concentration of 50 mM
Solution G: PBS containing sodium taurodeoxycholate at a concentration of 5% (w / v).

The measurement results are shown in FIG. As shown in FIG. 9, when sodium taurodeoxycholate, which is a positive control, was administered, the LDH concentration in the intestinal fluid was extremely higher than when PBS was administered. This indicates that the integrity of the intestinal epithelium was disrupted by sodium taurodeoxycholate, so that LDH originally present in the cell leaked through the intestinal epithelium. On the other hand, the LDH concentration in the intestinal fluid when tryptophan was administered had almost no change from that when PBS was administered, so tryptophan has very little effect on the integrity of the intestinal epithelial tissue and is safe. It was shown to be a high component.

Test Example 10 : In vivo oral administration test In mice after a 24-hour fast, insulin (50 IU / kg), L-arginine (200 mM), or insulin and L-arginine (40 or 200 mM) (100 μL) mixed solution Was orally administered using an oral sonde (i..d. 0.9 × length 50 mm) (Natsume Seisakusho Co., Ltd., Tokyo, Japan). Before administration, and 15, 30, 60, 120, 180, 240, 300, and 360 minutes after administration, blood was collected from the tail vein (one drop), and blood glucose level was measured over time with One Touch Ultra View (Johnson & Johnson KK, Tokyo, Japan).

The measurement results are shown in FIG. As shown in FIG. 10, the blood glucose level was not suppressed by oral administration of insulin or L-arginine alone, but the blood glucose level was suppressed by oral administration of insulin with L-arginine.

Claims

(Component a) basic amino acid,
(B component) A transmucosal absorption enhancer of a drug, comprising at least one selected from the group consisting of (b component) a peptide composed of 2 to 5 basic amino acids, and (c component) tryptophan.
The transmucosal absorption enhancer according to claim 1, wherein the basic amino acid is an L-amino acid.
The transmucosal absorption enhancer according to claim 1 or 2, comprising the component a.
The transmucosal absorption enhancer according to any one of claims 1 to 3, wherein the basic amino acid is at least one selected from the group consisting of arginine, lysine, and histidine.
The transmucosal absorption enhancer according to any one of claims 1 to 4, wherein the basic amino acid is arginine.
The transmucosal absorption promoter according to any one of claims 1 to 5, wherein the component b is a peptide composed of 2 to 4 basic amino acids.
The transmucosal absorption promoter according to any one of claims 1 to 6, comprising the component c.
The transmucosal absorption enhancer according to any one of claims 1 to 7, wherein the mucosa is intestinal mucosa.
The transmucosal absorption promoter according to any one of claims 1 to 8, wherein the drug has an isoelectric point of 7 or less.
The transmucosal absorption enhancer according to any one of claims 1 to 9, wherein the drug is a peptide or a protein.
A pharmaceutical composition comprising the transmucosal absorption enhancer according to any one of claims 1 to 10 and a drug.
The pharmaceutical composition according to claim 11, which is a solid preparation.
The pharmaceutical composition according to claim 11 or 12, which is an oral preparation.